Cerus Corporation (NASDAQ: CERS) (Seite 7)
eröffnet am 25.05.17 16:58:43 von
neuester Beitrag 03.05.24 00:07:48 von
neuester Beitrag 03.05.24 00:07:48 von
Beiträge: 219
ID: 1.253.751
ID: 1.253.751
Aufrufe heute: 0
Gesamt: 12.834
Gesamt: 12.834
Aktive User: 0
ISIN: US1570851014 · WKN: 905249
1,7100
EUR
+3,01 %
+0,0500 EUR
Letzter Kurs 07.05.24 Lang & Schwarz
Neuigkeiten
02.05.24 · Business Wire (engl.)  |
18.04.24 · Business Wire (engl.) |
26.03.24 · Business Wire (engl.) |
19.03.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | +49,07 | |
| 1,1600 | +40,52 | |
| 4,6900 | +28,49 | |
| 5,1200 | +28,00 | |
| 1,4799 | +26,49 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7212 | -16,89 | |
| 1,3800 | -20,80 | |
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 55.441.059 von occitania am 02.08.17 10:19:41Salut
News
https://finance.yahoo.com/news/cerus-enters-40-million-amend…
Zitate:
Cerus Corporation ( CERS ) gab heute bekannt, dass es in eine 40 Millionen Dollar geänderte Wachstums-Kapital-Kredit-Anlage mit Oxford Finance LLC, ein Spezial-Finanz-Unternehmen, das Senior Schulden für Life Sciences und Gesundheitsdienstleistungen Unternehmen weltweit bietet eingegeben hat. Im Rahmen der geänderten Fazilität erhielt Cerus am 31. Juli 2017 ein sofortiges Darlehen in Höhe von 30 Millionen US-Dollar und hat die Möglichkeit, weitere 10 Millionen Dollar an die Erreichung eines bestimmten Ertragsmeilensteins zu ziehen......
à bientôt
OC
News nach news und wir gehen jeden Tag noch tiefer...
Verstehe ...tue ich HIER...nicht mehr.
News
https://finance.yahoo.com/news/cerus-enters-40-million-amend…
Zitate:
Cerus Corporation ( CERS ) gab heute bekannt, dass es in eine 40 Millionen Dollar geänderte Wachstums-Kapital-Kredit-Anlage mit Oxford Finance LLC, ein Spezial-Finanz-Unternehmen, das Senior Schulden für Life Sciences und Gesundheitsdienstleistungen Unternehmen weltweit bietet eingegeben hat. Im Rahmen der geänderten Fazilität erhielt Cerus am 31. Juli 2017 ein sofortiges Darlehen in Höhe von 30 Millionen US-Dollar und hat die Möglichkeit, weitere 10 Millionen Dollar an die Erreichung eines bestimmten Ertragsmeilensteins zu ziehen......
à bientôt
OC
News nach news und wir gehen jeden Tag noch tiefer...
Verstehe ...tue ich HIER...nicht mehr.
Antwort auf Beitrag Nr.: 55.434.576 von occitania am 01.08.17 14:55:32Salut
Bin auch der Meinung...bis Obere Bollinger Band--->2,37 $
à bientôt
OC
Bin auch der Meinung...bis Obere Bollinger Band--->2,37 $
à bientôt
OC
Antwort auf Beitrag Nr.: 55.422.066 von occitania am 30.07.17 17:09:13Salut
News
https://finance.yahoo.com/news/cerus-announces-expanded-supp…
CONCORD, California--(BUSINESS WIRE)--August 1, 2017
Cerus Corporation (CERS) announced today the signing of two, new, expanded contracts with Établissement Français du Sang
(EFS), the French National Blood Service, for the INTERCEPT Blood System. One contract covers the supply of INTERCEPT Platelet kits while the other is for the purchase of additional Illuminators to help support the roll-out to new regions. The initial term of this platelet kit supply agreement is two years with two one-year extension options, supporting INTERCEPT platelet production in all EFS regional centers.
“We are proud that our decade long relationship with the EFS has led to an expanded supply agreement that supports a new standard of care,” said William ‘Obi” Greenman, Cerus’ president and chief executive officer. “Currently, approximately 10% of the annual platelet production in France is treated with the INTERCEPT system. We look forward to working with EFS to implement pathogen reduction throughout their system. In support of this broad roll-out to new regions, we plan to ramp up production of INTERCEPT Platelet kits to ensure ample supply,” continued Greenman.
In January, the EFS was informed of the Ministry of Health’s decision that the INTERCEPT Platelet system should be deployed for the control of bacterial infections transmitted by transfusion, in accordance with a prior December 2016 recommendation by France’s regulatory authority, ANSM, the French National Agency for Medicines and Health Products Safety.
The EFS produces approximately 330,000 units of platelets annually across 12 regional centers in continental France and 3 overseas territories. The INTERCEPT Blood System for platelets has been used in France since 2006, and is currently used in the Alsace region, as well as throughout overseas French territories including the islands of La Reunion, Guadeloupe, and Martinique. Implementation in the island territories was driven by the need to maintain a safe platelet supply during outbreaks of chikungunya, dengue and Zika in these tropical regions. In addition, INTERCEPT is utilized by the French Army.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for information about Cerus.
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding the expected implementation of the INTERCEPT Blood System through the EFS regional centers, as well as Cerus’ plans to ramp up production of disposable kits. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the implementation and use of the INTERCEPT Blood System, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including Cerus’ Annual Report on Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 4, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.
à bientôt
OC
News
https://finance.yahoo.com/news/cerus-announces-expanded-supp…
CONCORD, California--(BUSINESS WIRE)--August 1, 2017
Cerus Corporation (CERS) announced today the signing of two, new, expanded contracts with Établissement Français du Sang
(EFS), the French National Blood Service, for the INTERCEPT Blood System. One contract covers the supply of INTERCEPT Platelet kits while the other is for the purchase of additional Illuminators to help support the roll-out to new regions. The initial term of this platelet kit supply agreement is two years with two one-year extension options, supporting INTERCEPT platelet production in all EFS regional centers.“We are proud that our decade long relationship with the EFS has led to an expanded supply agreement that supports a new standard of care,” said William ‘Obi” Greenman, Cerus’ president and chief executive officer. “Currently, approximately 10% of the annual platelet production in France is treated with the INTERCEPT system. We look forward to working with EFS to implement pathogen reduction throughout their system. In support of this broad roll-out to new regions, we plan to ramp up production of INTERCEPT Platelet kits to ensure ample supply,” continued Greenman.
In January, the EFS was informed of the Ministry of Health’s decision that the INTERCEPT Platelet system should be deployed for the control of bacterial infections transmitted by transfusion, in accordance with a prior December 2016 recommendation by France’s regulatory authority, ANSM, the French National Agency for Medicines and Health Products Safety.
The EFS produces approximately 330,000 units of platelets annually across 12 regional centers in continental France and 3 overseas territories. The INTERCEPT Blood System for platelets has been used in France since 2006, and is currently used in the Alsace region, as well as throughout overseas French territories including the islands of La Reunion, Guadeloupe, and Martinique. Implementation in the island territories was driven by the need to maintain a safe platelet supply during outbreaks of chikungunya, dengue and Zika in these tropical regions. In addition, INTERCEPT is utilized by the French Army.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for information about Cerus.
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding the expected implementation of the INTERCEPT Blood System through the EFS regional centers, as well as Cerus’ plans to ramp up production of disposable kits. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the implementation and use of the INTERCEPT Blood System, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including Cerus’ Annual Report on Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 4, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.
à bientôt
OC
Antwort auf Beitrag Nr.: 55.418.462 von occitania am 29.07.17 13:09:00Salut
ab 03:32 Min CERS chart
à bientôt
OC
ab 03:32 Min CERS chart
à bientôt
OC
Antwort auf Beitrag Nr.: 55.410.440 von occitania am 28.07.17 10:16:10Salut
@ reaaalist
hey meiner lieber Freund,ich bin für eine Weile außer Betrieb..
nur im Fall der Fall ...poste ich bei Wallstreet ,möglich ist auch eine Abmeldung...aber ich vermute das ich angemeldet bleibe...sonst verliere ich viel Virtuelle Freundschaft und deine ist mir wichtig
also...bis denne
occitania
@ reaaalist
hey meiner lieber Freund,ich bin für eine Weile außer Betrieb..
nur im Fall der Fall ...poste ich bei Wallstreet ,möglich ist auch eine Abmeldung...aber ich vermute das ich angemeldet bleibe...sonst verliere ich viel Virtuelle Freundschaft und deine ist mir wichtig
also...bis denne
occitania
Trading Spotlight
Antwort auf Beitrag Nr.: 55.408.598 von occitania am 27.07.17 22:39:50Salut
Chart
https://claytrader.com/stock_chart/CERS/?utm_source=social&u…
à bientôt
OC
Chart
https://claytrader.com/stock_chart/CERS/?utm_source=social&u…
à bientôt
OC
Antwort auf Beitrag Nr.: 55.408.550 von reaaalist am 27.07.17 22:30:31Salut reaaalist
Tja bei 2,64 $ hat dem Finger gejuckt...Ich habe auch Heute früh nochmal 1 Ladung gekauft
Auf eine Chartanalyse heraus...und Bingo..dann kam die News
Ich habe gelesen...es wäre etwa 1 Million Einheit durch den Deal mit 150$-200 $ verdient dazu (laut User Fotd bei Yahoo)
Quelle:https://finance.yahoo.com/quote/CERS/community?p=CERS" target="_blank" rel="nofollow ugc noopener">https://finance.yahoo.com/quote/CERS/community?p=CERS
Ich verkauft zuerst ab 4 $...
à bientôt
OC
Tja bei 2,64 $ hat dem Finger gejuckt...Ich habe auch Heute früh nochmal 1 Ladung gekauft
Auf eine Chartanalyse heraus...und Bingo..dann kam die News
Ich habe gelesen...es wäre etwa 1 Million Einheit durch den Deal mit 150$-200 $ verdient dazu (laut User Fotd bei Yahoo)
Quelle:https://finance.yahoo.com/quote/CERS/community?p=CERS" target="_blank" rel="nofollow ugc noopener">https://finance.yahoo.com/quote/CERS/community?p=CERS
Ich verkauft zuerst ab 4 $...
à bientôt
OC
Antwort auf Beitrag Nr.: 55.408.463 von occitania am 27.07.17 22:14:36toll 
nun kann es mal richtig losgehen, ich bleibe optimistisch!
Ist einfach noch viel zu günstig, dieses Papier
Lieben Gruß
nun kann es mal richtig losgehen, ich bleibe optimistisch!
Ist einfach noch viel zu günstig, dieses Papier
Lieben Gruß
Antwort auf Beitrag Nr.: 55.406.996 von reaaalist am 27.07.17 18:47:40Salut reaaalist
gibt es einen guten Grund für diesen Ausbruch?
News...,meiner lieber...News
Cerus Announces Collaboration with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate
Quelle:https://www.wallstreet-online.de/nachricht/9774758-cerus-ann…
à bientôt
OC
gibt es einen guten Grund für diesen Ausbruch?
News...,meiner lieber...News
Cerus Announces Collaboration with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate
Quelle:https://www.wallstreet-online.de/nachricht/9774758-cerus-ann…
à bientôt
OC
Antwort auf Beitrag Nr.: 55.406.003 von occitania am 27.07.17 16:44:14Moin Occi
was ist los heute?
gibt es einen guten Grund für diesen Ausbruch?
oder ist das nur eine technische Reaktion
was ist los heute?
gibt es einen guten Grund für diesen Ausbruch?
oder ist das nur eine technische Reaktion
Durchsuchen
Cerus Corporation (NASDAQ: CERS)
